Literature DB >> 25806326

Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer.

Sacha I Rothschild1.   

Abstract

Entities:  

Year:  2014        PMID: 25806326      PMCID: PMC4367664          DOI: 10.3978/j.issn.2218-6751.2014.11.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  9 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Authors:  Giorgio Scagliotti; Rolf A Stahel; Rafael Rosell; Nick Thatcher; Jean-Charles Soria
Journal:  Eur J Cancer       Date:  2012-03-06       Impact factor: 9.162

4.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

5.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

Review 6.  Crizotinib in the treatment of non--small-cell lung cancer.

Authors:  Sacha I Rothschild; Oliver Gautschi
Journal:  Clin Lung Cancer       Date:  2013-06-20       Impact factor: 4.785

7.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  A genomics-based classification of human lung tumors.

Authors: 
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

  9 in total
  3 in total

1.  Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Authors:  Esra A Akbay; Shohei Koyama; Yan Liu; Ruben Dries; Lauren E Bufe; Michael Silkes; Md Maksudul Alam; Dillon M Magee; Robert Jones; Masahisa Jinushi; Meghana Kulkarni; Julian Carretero; Xiaoen Wang; Tiquella Warner-Hatten; Jillian D Cavanaugh; Akio Osa; Atsushi Kumanogoh; Gordon J Freeman; Mark M Awad; David C Christiani; Raphael Bueno; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  J Thorac Oncol       Date:  2017-05-06       Impact factor: 15.609

2.  Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors.

Authors:  Yunju Nam; Dongkeun Hwang; Namdoo Kim; Hong-Seog Seo; Khalid B Selim; Taebo Sim
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

3.  Clinical potential of gene mutations in lung cancer.

Authors:  Miranda B Carper; Pier Paolo Claudio
Journal:  Clin Transl Med       Date:  2015-11-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.